INVA as reported
Innoviva, Inc. reported $421M of revenue over the trailing twelve months, +14% on the year before. 11 reported series are charted on this page, each one as filed.
$421M
Revenue, trailing twelve months · to Q1 2026 · +14% against the twelve months before
- Net Income
- $504M
Net Income · −944% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $132M
Free Cash Flow · −34% year on year · trailing twelve months to Q1 2026
- Op Margin
- 38%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $421M | +14% | Q1 2026 |
| Net Income | $504M | −944% | Q1 2026 |
| EPS | $6.02 | −727% | Q1 2026 |
| Gross Margin | 74% | n/a | Q1 2026 |
| Op Margin | 38% | n/a | Q1 2026 |
| Net Margin | 120% | n/a | Q1 2026 |
| ROE | 20% | n/a | Q1 2026 |
| ROA | 14% | n/a | Q1 2026 |
| ROIC | 16% | n/a | Q1 2026 |
| Free Cash Flow | $132M | −34% | Q1 2026 |
| P/E | 3.53 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Innoviva, Inc. (INVA) - Revenue & ProfitRevenue & ProfitInnoviva, Inc. (INVA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Biotechnology
Ranks #24 of 145 by Smart Score